Q-omics provides the consensus-scored IL31 profile across patient tissues and cancer cell-line models. IL31 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, IL31 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, IL31 RNA expression shows 6,496 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, and STAD as cancer lineages where IL31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL31 survival associations across molecular data types. IL31 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL31 RNA expression–survival associations across cancer types. High IL31 expression shows unfavorable associations in THCA, LIHC, COAD and LUAD, but favorable associations in LUSC and SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for IL31 RNA expression.
This table summarizes IL31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IL31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL31 shows lower tumor expression in THCA and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher IL31 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p = .017).
This table shows molecular features associated with IL31 in patient tissues and cancer cell lines. In patient samples, IL31 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IL31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BREAST.
